{"id":1760,"text":"Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy.","label":[[0,43,"Herb name"],[28,43,"Extraction process"],[56,66,"Pathology"]],"Comments":[]}
{"id":1761,"text":"Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered.","label":[[29,53,"Pathology"],[65,70,"Sex"],[72,91,"Drug"],[96,103,"Herb name"]],"Comments":[]}
{"id":1762,"text":"A double-blind, randomised, 2-period crossover study was performed to investigate the effects of Silexan on the pharmacokinetics and pharmacodynamics of Microgynon A total of 24 women (mean age 27.3 years; mean body mass index 22.2 kg\/m Co-administration of Silexan did not affect the efficacy of a combination oral contraceptive containing EE and LNG and was well tolerated.","label":[[0,52,"Study"],[97,104,"Herb name"],[108,163,"Parameter"],[153,163,"Drug"],[164,183,"Cohort"],[178,183,"Sex"],[194,204,"Age"],[211,226,"Parameter"],[227,236,"Amount"],[258,265,"Herb name"],[310,329,"Drug"],[341,343,"Drug"],[348,351,"Drug"]],"Comments":[]}
{"id":1763,"text":"Silexan1 is a preparation from Lavandula angustifolia for oral use that is obtained from the flowering tops of the plant by steam distillation, and that complies with the monograph Lavender oil of the European Pharmacopoeia [1] with respect to all quality parameters.","label":[[0,53,"Herb name"],[89,120,"Herb part"],[121,142,"Extraction process"],[181,193,"Herb name"],[190,193,"Extraction process"]],"Comments":[]}
{"id":1764,"text":"It exceeds the quality definition of the pharmacopoeial monograph with respect to items that are important for efficacy and tolerability.","label":[],"Comments":[]}
{"id":1765,"text":"Randomised controlled clinical trials have demonstrated that Silexan is a potent anxiolytic drug with superior efficacy compared with placebo in subsyndromal anxiety disorder [2].","label":[[0,37,"Study"],[61,68,"Herb name"],[81,91,"Pathology"],[145,174,"Pathology"]],"Comments":[]}
{"id":1766,"text":"In generalised anxiety disorder (GAD), Silexan was found to be comparably efficacious as lorazepam [3] and at least as efficacious as paroxetine.","label":[[3,37,"Pathology"],[39,46,"Herb name"],[89,98,"Drug"],[134,144,"Drug"]],"Comments":[]}
{"id":1767,"text":"The drug has a marketing authorisation in Germany for the symptomatic treatment of restlessness related to anxious mood, with a recommended dosage of 80 mg\/d.","label":[[83,119,"Pathology"],[150,157,"Amount"]],"Comments":[]}
{"id":1768,"text":"While Silexan is a complex, multi-ingredient mixture, its anxiolytic properties have been ascribed in particular to linalool and linalyl acetate [4].","label":[[6,13,"Herb name"],[58,68,"Pathology"],[116,144,"Herb name"]],"Comments":[]}
{"id":1769,"text":"Anxiety disorders are by far the most prevalent psychiatric conditions in Western Europe and the USA [5, 6].","label":[[0,17,"Pathology"],[48,70,"Pathology"]],"Comments":[]}
{"id":1770,"text":"Their prevalence in women is at least twice as high as in men [7, 8].","label":[[20,25,"Sex"],[58,61,"Sex"]],"Comments":[]}
{"id":1771,"text":"Since the prevalence of anxiety disorders tends to decrease rather than to increase with age [9], a substantial proportion of the patients who seek treatment for anxiety are women of childbearing potential who may be practising oral contraception.","label":[[24,41,"Pathology"],[162,169,"Pathology"],[174,179,"Sex"],[183,205,"Parameter"],[228,246,"Drug"]],"Comments":[]}
{"id":1772,"text":"The steroid hormones contained in oral contraceptives are metabolised mainly through hydroxylation in the liver.","label":[[0,53,"Drug"],[85,98,"Parameter"]],"Comments":[]}
{"id":1773,"text":"Drugs that induce the cytochrome P450 (CYP) enzyme system, notably CYP3A4, reduce the bioavailability by increasing the first-pass metabolism of the oral contraceptive steroids and may therefore impair their efficacy, leading to breakthrough bleeding and, possibly, unwanted pregnancy [10, 11].","label":[[18,73,"Target"],[82,101,"Parameter"],[116,176,"Parameter"],[208,216,"Parameter"],[229,250,"Pathology"],[266,284,"Parameter"]],"Comments":[]}
{"id":1774,"text":"A comprehensive list of drugs that induce CYP has been published by Rendic [12].","label":[[42,45,"Target"]],"Comments":[]}
{"id":1775,"text":"They include several anticonvulsants and broad spectrum antibiotics, rifampicin, griseofulvin, and anti-retroviral drugs.","label":[[21,120,"Drug"]],"Comments":[]}
{"id":1776,"text":"Bioavailability is the rate and extent to which the active substance or active moiety is absorbed from a pharmaceutical form and becomes available at the site of action [13].","label":[[0,15,"Parameter"]],"Comments":[]}
{"id":1777,"text":"As the use of herbal preparations increases in the general population, the potential for herb–drug interactions also increases.","label":[[14,33,"Herb name"]],"Comments":[]}
{"id":1778,"text":"Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].","label":[[11,26,"Herb name"],[54,73,"Parameter"]],"Comments":[]}
{"id":1779,"text":"Since women of childbearing potential who practise oral contraception represent an important part of the target population for which Silexan is intended, it is important to investigate whether the herbal drug may have an effect on the bioavailability and efficacy of oral contraceptives.","label":[[6,11,"Sex"],[15,37,"Parameter"],[51,69,"Drug"],[133,140,"Herb name"],[193,208,"Herb name"],[231,286,"Parameter"]],"Comments":[]}
{"id":1780,"text":"Although a clinical study showed no induction of the CYP enzymes 1A2, 2C9, 2C19, 2D6 and 3A4 [15], suggesting that no increased activity in metabolization of contraceptive ingredients occurs during co-administration of Silexan, some examples of inhibition of phase-II enzymes, mainly UDP-glucuronosyltransferases (UGTs), by co-administered herbal drugs (e. g., Williams et al.","label":[[9,25,"Study"],[49,92,"Parameter"],[128,183,"Parameter"],[219,226,"Herb name"],[259,319,"Target"],[340,352,"Herb name"]],"Comments":[]}
{"id":1781,"text":"[16]) do exist.","label":[],"Comments":[]}
{"id":1782,"text":"This study was therefore performed to investigate the relative bioavailability of ethinyl estradiol (EE) and levonorgestrel (LNG), the active ingredients of the monophasic combination oral contraceptive Microgynon The investigation was performed as a double-blind, randomised, placebo-controlled, monocentric, crossover study in healthy volunteers whose primary objective was to assess the interacting potential of Silexan with the pharmacokinetic properties of EE and LNG, the active ingredients of the combination oral contraceptive Microgynon The protocol was reviewed and approved by an independent ethics committee.","label":[[50,129,"Parameter"],[82,213,"Drug"],[249,325,"Study"],[329,336,"Pathology"],[415,422,"Herb name"],[428,472,"Parameter"],[462,545,"Drug"]],"Comments":[]}
{"id":1783,"text":"All subjects provided written informed consent.","label":[],"Comments":[]}
{"id":1784,"text":"The principles of Good Clinical Practice and the Declaration of Helsinki were adhered to.","label":[],"Comments":[]}
{"id":1785,"text":"The study participants were healthy, female, premenopausal volunteers aged between 18 and 38 years (smokers had to be ≤30 years of age, and those with a consumption of more than ten cigarettes per day were excluded), who presented with a body mass index between 18 and 30 kg\/m During study participation, the subjects were not allowed to take any of the following drugs: any drugs known or discussed to potentially induce liver enzymes (e.g.","label":[[28,35,"Pathology"],[37,43,"Sex"],[45,58,"Parameter"],[75,98,"Age"],[100,107,"Parameter"],[118,134,"Age"],[146,200,"Parameter"],[178,200,"Frequency"],[236,253,"Parameter"],[254,276,"Amount"],[371,435,"Drug"],[422,435,"Target"]],"Comments":[]}
{"id":1786,"text":"rifampicin, dexamethasone, barbiturates, anticonvulsants, St. John’s wort); any drugs known to inhibit CYP3A4 (e.g.","label":[[0,56,"Drug"],[58,73,"Herb name"],[103,109,"Target"]],"Comments":[]}
{"id":1787,"text":"ketoconazole, verapamil, cimetidine, macrolides); any broad-spectrum antibiotics; and long-acting, injectable or implant hormonal therapy within 26 weeks prior to the screening visit, as well as any oral contraceptives other than the investigational treatment.","label":[[0,137,"Drug"],[145,153,"Duration"],[199,218,"Drug"]],"Comments":[]}
{"id":1788,"text":"Silexan was presented in immediate-release soft gelatine capsules containing 160 mg of lavender oil.","label":[[0,7,"Herb name"],[25,99,"Extraction process"],[77,83,"Amount"]],"Comments":[]}
{"id":1789,"text":"An identically matched placebo was available in which the smell of the study drug was concealed by flavouring the capsules with 0.08 mg of Lavender oil, i.e., with 1\/2000 of the amount of Lavender oil contained in the active capsules.","label":[[128,135,"Amount"],[139,151,"Herb name"],[148,151,"Extraction process"],[164,200,"Amount"],[188,200,"Herb name"],[197,200,"Extraction process"]],"Comments":[]}
{"id":1790,"text":"During randomised treatment, the subjects had to take one capsule of Silexan or placebo per day in the morning unchewed.","label":[[54,65,"Amount"],[69,76,"Herb name"],[88,95,"Frequency"]],"Comments":[]}
{"id":1791,"text":"A daily dose of 160 mg corresponds to twice the currently recommended dose of the marketed product.","label":[[0,12,"Frequency"],[16,22,"Amount"]],"Comments":[]}
{"id":1792,"text":"Moreover, Silexan 160 mg\/day has been shown to be highly efficacious in patients with GAD [17].","label":[[10,17,"Herb name"],[18,24,"Amount"],[24,28,"Frequency"],[86,89,"Pathology"]],"Comments":[]}
{"id":1793,"text":"Microgynon The study participants had to complete at least 2 cycles of oral contraception with Microgynon Study schedule    EE ethinyl estradiol, LNG levonorgestrel, PK pharmacokinetics, PL placebo, SIL Silexan During randomised treatment, weekly visits were scheduled on days 7, 14, 21, and 28 of each cycle.","label":[[0,10,"Drug"],[71,105,"Drug"],[124,164,"Drug"],[166,185,"Parameter"],[198,210,"Herb name"]],"Comments":[]}
{"id":1794,"text":"For each visit, a deviation of ±1 day was permitted.","label":[[31,37,"Duration"]],"Comments":[]}
{"id":1795,"text":"In addition, blood sampling for determining the pharmacokinetic (PK) parameters of EE and LNG was performed on 4 consecutive days starting on day 18 ± 1 day of each cycle: on each of these days EE and LNG trough levels were determined.","label":[[44,93,"Parameter"],[83,93,"Drug"],[194,204,"Drug"],[194,218,"Parameter"]],"Comments":[]}
{"id":1796,"text":"Furthermore, blood samples for determining PK profiles were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after the intake of Microgynon The primary outcome measures for assessing potential pharmacological interactions between Silexan and the combination oral contraceptive were the area under the curve over a dosing interval of τ = 24 h (AUCτ) derived from the 24-h concentration–time curves for EE and LNG at steady state.","label":[[43,54,"Parameter"],[72,114,"Duration"],[129,139,"Drug"],[230,237,"Herb name"],[258,276,"Drug"],[282,348,"Parameter"],[361,411,"Parameter"],[366,370,"Duration"],[401,411,"Drug"]],"Comments":[]}
{"id":1797,"text":"Secondary outcome measures included the EE and LNG peak concentration (C  Assessment of safety and tolerability was based on spontaneous reports of adverse events (AEs), physical examinations and safety laboratory measurements.","label":[[36,72,"Parameter"],[40,50,"Drug"],[88,111,"Parameter"],[148,168,"Pathology"],[170,226,"Parameter"]],"Comments":[]}
{"id":1798,"text":"After subjects were determined as eligible for the trial, they were randomised to treatment with Silexan followed by placebo, or vice versa, at a ratio of 1:1.","label":[[47,56,"Study"],[97,104,"Herb name"]],"Comments":[]}
{"id":1799,"text":"Fixed block randomisation was used; however, the investigator was not informed about the random block size until completion of the trial.","label":[[127,136,"Study"]],"Comments":[]}
{"id":1800,"text":"A biometrician otherwise not involved in the trial generated the code using a validated computer program.","label":[[41,50,"Study"]],"Comments":[]}
{"id":1801,"text":"Upon inclusion into randomised treatment, each subject received the lowest available number.","label":[],"Comments":[]}
{"id":1802,"text":"PK parameters were derived by non-compartmental methods using Phoenix WinNonlin PK measures determined from the EE and LNG concentration-time profiles were compared between Silexan and placebo using analysis of variance (ANOVA) models with main effects for sequence, subject within sequence, period, and treatment.","label":[[0,13,"Parameter"],[80,91,"Parameter"],[108,150,"Parameter"],[112,122,"Drug"],[173,180,"Herb name"]],"Comments":[]}
{"id":1803,"text":"Tests for AUCτ and C  In the absence of other guidance, the assessment of the pharmacological interacting potential of Silexan was based on the same approach as when testing for bioequivalence [21]: the absence of a clinically relevant PK interaction between Silexan and EE or LNG was concluded if the 90 % confidence intervals for the AUCτ ratios (Silexan\/placebo) determined from the ANOVA models were included within the standard 80–125 % equivalence range.","label":[[10,14,"Parameter"],[19,20,"Parameter"],[119,126,"Herb name"],[178,192,"Parameter"],[259,266,"Herb name"],[271,280,"Drug"],[336,340,"Parameter"],[349,356,"Herb name"]],"Comments":[]}
{"id":1804,"text":"Since the confidence intervals for the AUCτ ratios of both hormones were required to fall within the pre-specified equivalence range simultaneously, type I error level adjustment for multiple testing was not required.","label":[[35,50,"Parameter"],[54,67,"Drug"]],"Comments":[]}
{"id":1805,"text":"Comparable ANOVA models were also applied to C  The sample size estimation was based on the assumption of a true within-subject coefficient of variation of 20 % for ln(AUCτ) of both EE and LNG.","label":[[45,46,"Parameter"],[168,172,"Parameter"],[182,192,"Drug"]],"Comments":[]}
{"id":1806,"text":"When the true AUCτ ratio between Silexan and placebo is between 0.95 and 1.05, a sample size of 20 subjects will have at least 80 % power for rejecting the null hypothesis predicting an interaction between Silexan and EE or LNG according to the above criteria.","label":[[14,24,"Parameter"],[33,40,"Herb name"],[56,77,"Amount"],[96,107,"Cohort"],[206,213,"Herb name"],[218,227,"Drug"]],"Comments":[]}
{"id":1807,"text":"In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.","label":[[90,112,"Cohort"]],"Comments":[]}
{"id":1808,"text":"Between November 2009 and May 2010, a total of 32 women were included and 24 were randomised and treated.","label":[[0,34,"Duration"],[36,55,"Cohort"],[50,55,"Sex"]],"Comments":[]}
{"id":1809,"text":"All randomised subjects completed the study as scheduled.","label":[],"Comments":[]}
{"id":1810,"text":"All treated subjects were analysed for safety.","label":[],"Comments":[]}
{"id":1811,"text":"Two subjects were excluded from all PK and pharmacodynamic (PD) analyses; one took prohibited concomitant medication and one missed one dose of Microgynon The randomised study participants were aged between 21 and 37 years (mean ± standard deviation [SD] 27.3 ± 4.1 years) and had a body mass index ranging between 19.3 and 26.8 kg\/m According to capsule counting, compliance with Silexan or placebo was 100 % in 23 of the 24 subjects.","label":[[83,116,"Drug"],[144,154,"Drug"],[199,222,"Age"],[255,271,"Age"],[281,298,"Parameter"],[307,333,"Amount"],[381,388,"Herb name"],[419,434,"Cohort"]],"Comments":[]}
{"id":1812,"text":"One woman took one additional capsule during the first treatment period and left out one during the second.","label":[[4,9,"Sex"],[15,37,"Amount"]],"Comments":[]}
{"id":1813,"text":"The analysis of linalool plasma concentrations confirmed that all participants had taken Silexan according to the randomisation, whereas the treatment sequence had been mixed up in one woman.","label":[[16,24,"Herb name"],[16,46,"Parameter"],[89,96,"Herb name"],[185,190,"Sex"]],"Comments":[]}
{"id":1814,"text":"Of the 24 randomised participants, 22 took Microgynon Main pharmacokinetic parameters (n = 22)     ANOVA analysis of variation, AUCτ area under the concentration–time curve over a dosing interval of τ = 24 h, CI confidence interval, C  Figure 1 shows the plasma concentration–time profiles for EE and LNG during co-administration of Silexan or placebo.","label":[[3,33,"Cohort"],[43,53,"Drug"],[128,207,"Parameter"],[203,207,"Duration"],[233,234,"Parameter"],[251,289,"Parameter"],[294,304,"Drug"],[333,340,"Herb name"]],"Comments":[]}
{"id":1815,"text":"The numerical results are presented in Table 2.","label":[],"Comments":[]}
{"id":1816,"text":"Plasma concentration–time profiles of EE (upper panel) and LNG (lower panel) over 28 days during treatment with Microgynon For EE and LNG, the 90 % confidence intervals for the AUCτ and C  The results for the main PD outcomes and biomarkers are summarised in Table 3.","label":[[0,62,"Parameter"],[38,40,"Drug"],[59,62,"Drug"],[82,89,"Duration"],[112,137,"Drug"],[173,181,"Parameter"],[186,187,"Parameter"]],"Comments":[]}
{"id":1817,"text":"The only case of an active follicle-like structure (>13 mm follicular growth accompanied by estradiol production) was observed during placebo treatment.","label":[[52,58,"Amount"],[59,76,"Parameter"],[92,101,"Parameter"]],"Comments":[]}
{"id":1818,"text":"Average follicle sizes decreased during Microgynon Summary of main pharmacodynamic outcomes Data are presented as mean ± SD or number (%)        SD standard deviation, SHBG sex hormone-binding globulin Comparable mean levels for progesterone, estradiol, and SHBG were observed during both treatment phases (Table 3).","label":[[40,50,"Drug"],[168,201,"Parameter"],[213,262,"Parameter"],[229,252,"Drug"]],"Comments":[]}
{"id":1819,"text":"Whereas progesterone showed only minor changes over time, estradiol decreased markedly until the end of the 2nd week of the cycles and continued to decrease slightly during the 3rd week, whereas a sharp average increase was observed in the pill-free 4th week.","label":[[8,20,"Drug"],[8,20,"Parameter"],[58,67,"Drug"],[58,67,"Parameter"],[87,130,"Duration"],[166,185,"Duration"],[250,258,"Duration"]],"Comments":[]}
{"id":1820,"text":"During the first 3 weeks of each cycle, while administering Microgynon Individual values for the linalool concentrations indicate that the PK evaluation has been performed after a steady state was reached.","label":[[0,38,"Duration"],[60,70,"Drug"],[97,105,"Herb name"],[97,120,"Parameter"]],"Comments":[]}
{"id":1821,"text":"During randomised treatment, 36 AEs were reported by 17 of the 24 women (70.8 %) under co-administration of Microgynon It is important to investigate whether anxiolytic drugs may modify the bioavailability and the clinical efficacy of oral contraceptives with steroid hormones.","label":[[32,35,"Pathology"],[66,71,"Sex"],[108,118,"Drug"],[158,174,"Drug"],[186,205,"Parameter"],[210,231,"Parameter"],[235,276,"Drug"]],"Comments":[]}
{"id":1822,"text":"The study demonstrates that Silexan does not show clinically relevant pharmacological interactions with EE or LNG, which are the active ingredients of Microgynon Smoking may alter the PK properties of oral contraceptive steroids.","label":[[28,35,"Herb name"],[104,113,"Drug"],[151,161,"Drug"],[162,169,"Parameter"],[180,228,"Parameter"],[201,228,"Drug"]],"Comments":[]}
{"id":1823,"text":"Since about one-third of the women in the study sample were mild smokers (subjects smoking more than ten cigarettes per day were excluded from participation), this might have contributed to large inter-individual variability in plasma concentrations, notably in EE.","label":[[29,34,"Sex"],[65,72,"Parameter"],[83,90,"Parameter"],[91,115,"Amount"],[116,123,"Frequency"],[228,249,"Parameter"],[262,264,"Drug"]],"Comments":[]}
{"id":1824,"text":"However, the inter- and intra-individual variability of the EE plasma levels in our trial was comparable with the literature [22] and, moreover, higher variability would have biased the data towards an acceptance of the null hypothesis predicting an interaction between Silexan and EE and\/or LNG.","label":[[56,76,"Parameter"],[60,62,"Drug"],[84,89,"Study"],[270,277,"Herb name"],[282,284,"Drug"],[292,295,"Drug"]],"Comments":[]}
{"id":1825,"text":"Since the null hypothesis could be rejected and an interaction could be excluded in accordance with the pre-specified criteria, an introduction of bias due to the inclusion of mild smokers can also be excluded.","label":[[181,188,"Parameter"]],"Comments":[]}
{"id":1826,"text":"Progesterone, estradiol, and SHBG level monitoring also did not indicate an impairment of the contraceptive efficacy of Microgynon Silexan had no appreciable effect on mean endometrial thickness and follicle size.","label":[[0,23,"Drug"],[0,39,"Parameter"],[120,130,"Drug"],[131,138,"Herb name"],[173,194,"Parameter"],[199,212,"Parameter"]],"Comments":[]}
{"id":1827,"text":"The measured individual follicle sizes were always within the range expected during adequate ovarian suppression [23], and a follicle size exceeding a threshold value of 13 mm was observed only once in a woman receiving placebo.","label":[[24,38,"Parameter"],[123,138,"Parameter"],[170,175,"Amount"],[204,209,"Sex"]],"Comments":[]}
{"id":1828,"text":"AEs observed during this trial in healthy volunteers were never more than moderately severe and temporary; abnormal laboratory values were more often related to the study procedures (e.g., to frequent blood sampling) than to study medication intake.","label":[[0,3,"Pathology"],[25,30,"Study"],[34,41,"Pathology"]],"Comments":[]}
{"id":1829,"text":"Among the events assessed to be potentially attributable to Silexan, the only effect that was observed in more than one subject but also not during placebo treatment was eructation.","label":[[60,67,"Herb name"],[170,180,"Pathology"]],"Comments":[]}
{"id":1830,"text":"Mild gastrointestinal disorders are among the known side effects of Silexan, but were always tolerable and did not interfere with treatment compliance.","label":[[0,31,"Pathology"],[52,64,"Pathology"],[68,75,"Herb name"]],"Comments":[]}
{"id":1831,"text":"In conclusion, Silexan, at a dose of 160 mg\/day, corresponding to twice the currently recommended dose, did not adversely affect the relative bioavailability and the suppressive efficacy on hormonal and ovarian status of the oral combination contraceptive Microgynon Silexan is the active substance of Lasea Trial registration: ISRCTN52706881, International Standard Randomised Controlled Trial Number Register.","label":[[15,22,"Herb name"],[37,43,"Amount"],[43,47,"Frequency"],[129,157,"Parameter"],[221,266,"Drug"],[267,274,"Herb name"],[302,307,"Herb name"]],"Comments":[]}
{"id":1832,"text":"This study was work for hire supported by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany (sponsor).","label":[],"Comments":[]}
{"id":1833,"text":"AD and SS are employees of Dr. Willmar Schwabe GmbH & Co. KG.","label":[],"Comments":[]}
{"id":1834,"text":"No further conflict of interest is declared.","label":[],"Comments":[]}
{"id":1835,"text":"Medical writing support was provided by Andreas Völp, psy consult scientific services, Frankfurt, Germany.","label":[],"Comments":[]}
